Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02446821 · ClinicalTrials.gov registry record · Phase 2
Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception
A Phase 2 study, sponsored by Sebela Women's Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 286
- Enrollment target
NCT02446821 is a Phase 2 study that has completed, run by Sebela Women's Health. The registered enrollment target is 286 participants.
The verdict
NCT02446821, a Phase 2 study, has completed, sponsored by Sebela Women's Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 286 participants
- Enrollment target
Study Summary
Prospective, multi-center, single-arm, open-label, Phase II clinical study to evaluate the effectiveness, device placement, safety, and tolerability of VeraCept to support commencing a Phase III Clinical Study
Interventions
- DRUG VeraCept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2015-06 |
| Est. Completion | 2019-03-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02446821
The ClinicalTrials.gov registry entry for NCT02446821 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 286 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sebela Women's Health, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VeraCept is the first listed.
NCT02446821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02446821 about?
NCT02446821 is a clinical study titled "Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception". Prospective, multi-center, single-arm, open-label, Phase II clinical study to evaluate the effectiveness, device placement, safety, and tolerability of VeraCept to support commencing a Phase III Clinical Study
What is the current status of trial NCT02446821?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 286 participants. The study started on 2015-06. Estimated completion is 2019-03-22.
What interventions are being tested in trial NCT02446821?
The interventions under investigation include: VeraCept (DRUG).
Who is sponsoring clinical trial NCT02446821?
This trial is sponsored by Sebela Women's Health, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.